METTL3 and cardiac hypertrophy: To determine the therapeutic effect of METTL3 knockdown in vivo, AAV9 was utilized to deliver shMETTL3 to the heart of mice via caudal vein 4 weeks before inducement of myocardial hypertrophy with Ang-II (Fig. 7A).